Journal
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Volume 25, Issue 1, Pages 45-47Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00000421-200202000-00009
Keywords
pyrazoloacridine; ovarian cancer
Categories
Funding
- NCI NIH HHS [CA 27469, CA 37517] Funding Source: Medline
Ask authors/readers for more resources
The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m(2) intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
